Guangzhou RiboBio Co.

Guangzhou, China

Guangzhou RiboBio Co.

Guangzhou, China
SEARCH FILTERS
Time filter
Source Type

Gong L.,South China Agricultural University | Yang X.,Guangzhou RiboBio Co. | Zhang B.,Guangzhou RiboBio Co. | Zhong G.,South China Agricultural University | Hu M.,South China Agricultural University
Pest Management Science | Year: 2011

BACKGROUND: Extensive applications and frequent long-term use of pesticides can affect behavioural mechanisms and physiological and biochemical aspects of insects, leading to resistance. However, insect control strategies involving a different mode of action would be valuable for managing the emergence of insect resistance. In this context, the development of RNA interference technology has brought a turning point in the creation of new biopesticides. RESULTS: Full-length cDNA of Rieske iron-sulfur protein (RISP) was cloned and characterised from Plutella xylostella L. Three siRNAs specific to RISP sequences were designed and chemically synthesised, and fed to P. xylostella larvae by coating cabbage leaves. This resulted in specific gene silencing of RISP, and consequently brought significant mortality of P. xylostella larvae compared with the control treatment. Silencing of RISP leads to significantly lower transcript levels of RISP compared with the control. In addition, the amount of ATP in the surviving larvae was lower than in the control. However, surviving larvae gradually recovered to normal transcript and protein levels. CONCLUSION: This is the first demonstration of the potential use of chemically synthesised siRNA in the development of new biopesticides as a mitochondrial electron transport inhibitor. © 2011 Society of Chemical Industry.


Wang D.,Copenhagen University | Wu L.-P.,Copenhagen University | Wu L.-P.,Guangzhou RiboBio Co.
Materials Science and Engineering C | Year: 2016

Billions of dollars have been invested in the therapeutic application of nucleic acid-based agents in humans in recent years. There are inspirable data from ongoing clinical trial for different diseases. However, in order to widely apply nucleic acid in prevention, diagnosis and treatment of age-related disease, such as neurodegeneration and disorders, suitable, safe and effective drug delivery nanocarriers have to been developed to overcome the blood brain barrier (BBB), which is the most inflexible barrier in human body. Here, we highlight the structure and function of barriers in the central nervous system (CNS) and summary several types of nanomaterials which can be potentially used in the brain delivery nucleic acid. © 2016 Elsevier B.V.


Zhou L.,Chinese Academy of Sciences | Zhou L.,University of Chinese Academy of Sciences | Chen Z.,Chinese Academy of Sciences | Wang F.,Chinese Academy of Sciences | And 3 more authors.
Acta Biomaterialia | Year: 2013

A non-viral siRNA carrier composed of mono-methoxy-poly (3-hydroxybutyrate-co-4-hydroxybutyrate)-block-polyethylene glycol-block-linear polyethyleneimine (mP3/4HB-b-PEG-b-lPEI) was synthesized using 1800 Da linear polyethyleneimine and evaluated for siRNA delivery. Our study demonstrated that siRNA could be efficiently combined with mP3/4HB-b-PEG-b-lPEI (mAG) co-polymer and was protected from nuclease degradation. The combined siRNA were released from the complexes easily under heparin competition. The particle size of the mAG/siRNA complexes was 158 nm, with a ζ-potential of around 28 mV. Atomic force microscopy images displayed spherical and homogeneously distributed complexes. The mAG block co-polymer displayed low cytotoxicity and efficient cellular uptake of Cy3-siRNA in A549 cells by flow cytometry and confocal microscopy. In vitro transfection efficiency of the block co-polymer was assessed using siRNA against luciferase in cultured A549-Luc, HeLa-Luc, HLF-Luc, A375-Luc and MCF-7-Luc cells. A higher transfection efficiency and lower cytotoxicity was obtained by mAG block co-polymer in five cell lines. Furthermore, a remarkable improvement in luciferase gene silencing efficiency of the mAG complex (up to 90-95%) over that of Lipofectamine™ 2000 (70-82%) was observed in HLF-Luc and A375-Luc cells. Additionally, a mAG/p65-siRNA complex also showed a better capability than Lipofectamine™ 2000/p65-siRNA complex to drastically reduce the p65 mRNA level down to 10-16% in HeLa, U251 and HUVEC cells at an N/P ratio of 70. Crown Copyright © 2013 Published by Elsevier Ltd. on behalf of Acta Materialia Inc. All rights reserved.


Liang P.,Chinese Academy of Sciences | Zhang H.,Chinese Academy of Sciences | Zhang H.,Hefei University of Technology | Wang G.,Chinese Academy of Sciences | And 4 more authors.
Traffic | Year: 2013

NF-κB/p65 is retained in the cytoplasm until it is activated in response to stress. Nuclear import of p65 is regulated by importin α in a nuclear localization signal (NLS)-dependent manner. However, the role of importin β family members in the nuclear translocation of p65 is largely unclear. In this study, using high-content siRNA screening, we identified three of 17 importin β family members that are involved in the nuclear import of p65. Our data showed that knockdown of KPNB1, XPO7 and IPO8 reduced the amount of nuclear p65 following tumor necrosis factor-α (TNF-α) stimulation, resulting in lower NF-κB activity. KPNB1 was the major importin β receptor for p65 import, and this import was dependent on the NLS of p65. However, NLS-mutated p65 still entered the nucleus and bound to XPO7 and IPO8. Interestingly, among the six members of the importin α family, KPNA2 was most important for p65 import. Taken together, our results show that the import of p65 mainly relies on the canonical KPNA2/KPNB1 pathway; however, p65 is also imported by an alternative pathway that is independent of its NLS. Redundant importin receptors are likely to maintain the important function of p65 according to need. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


Zhou L.,Chinese Academy of Sciences | Zhou L.,University of Chinese Academy of Sciences | Chen Z.,Chinese Academy of Sciences | Chi W.,Chinese Academy of Sciences | And 4 more authors.
Biomaterials | Year: 2012

A class of non-viral siRNA vectors consisting of biodegradable poly(hydroxyalkanoates) (PHA) grafted onto branched poly(ethyleneimine) (bPEI, 25kDa) was synthesized and evaluated for siRNA delivery. The mPHA- g-bPEI copolymers were synthesized through Michael addition between acrylated mono-methoxy-poly(hydroxyalkanoates) (mPHA-acrylated) and bPEI with various block length poly(hydroxyalkanoates) from 1300 to 2900Da. Our research showed that mPHA- g-bPEI copolymers could effectively bind siRNA, protect it from degradation by nucleases and efficiently release the complexed siRNA in the presence of low concentrations of polyanionic heparin. The particle size of mPHA- g-bPEI/siRNA complexes was <200nm with ζ-potential between 33 and 43mV. mPHA- g-bPEI copolymers displayed low cytotoxicity compared to unmodified bPEI and efficient cellular uptake of Cy3-siRNA in A549 cells by flow cytometry and confocal microscopy. siRNA delivery efficiency of the copolymers was assessed by siRNA against luciferase in cultured A549-Luc and MCF-7-Luc cells. Those mPHA- g-bPEI copolymers revealed a higher transfection efficiency and lower cytotoxicity than bPEI in two cell lines. Furthermore, a remarkable knockdown of luciferase expression of mPHA- g-bPEI (mAP2) complex (up to 85%) invitro was found to be equivalent to that of commercially available transfection agent Lipofectamine™ 2000. © 2011 Elsevier Ltd.


Ren X.-S.,Chinese Academy of Sciences | Ren X.-S.,Hefei University of Technology | Yin M.-H.,Chinese Academy of Sciences | Yin M.-H.,Hefei University of Technology | And 11 more authors.
Cancer Letters | Year: 2014

MicroRNA-449a (miR-449a) was significantly downregulated in 156 lung cancer tissues (p< 0.001). We found that the low expression of miR-449a was highly correlated with cancer recurrence and survival of lung cancer patients. The transient introduction of miR-449a caused cell cycle arrest and cell senescence in A549 and 95D cells. Further studies revealed that E2F3 was a direct target of miR-449a in lung cancer cells. miR-449a also suppressed tumor formation in vivo in nude mice. These results suggest that miR-449a plays an important role in lung cancer tumorigenesis and that miR-449a might predict cancer recurrence and survival of lung cancer patients. © 2013 Elsevier Ireland Ltd.


Yang L.,Dalian Medical University | Long Y.,324 Hospital Of Chinese Peoples Liberation Army | Li C.,Dalian Medical University | Cao L.,Guangzhou RiboBio Co. | And 3 more authors.
Japanese Journal of Infectious Diseases | Year: 2015

Long noncoding RNAs (lncRNAs) are an important class of pervasive genes, and their misregulation has been shown in various types of diseases. However, the relationship between lncRNAs and the immune response to pathogen infection has been rarely reported. Helicobacter pylori is a major human pathogenic bacterium that causes gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. The regulatory mechanism of the H. pylori-induced immune response is not yet clear. In the present study, we identified nonoverlapping signatures of a small number of lncRNAs that were aberrantly expressed in H. pylori-infected gastric epithelial cells using microarray analysis followed by bioassays. From microarray data, we found that 23 lncRNAs were upregulated and 21 were downregulated. Five lncRNAs, XLOC_004562, XLOC_005912, XLOC_000620, XLOC_004122, and XLOC_014388, were further evaluated using quantitative reverse transcription-PCR, and the results matched well with microarray data. In addition, XLOC_004122 and XLOC_014388 were decreased in gastric mucosal tissues of H. pylori-positive patients. Differentially expressed lncRNAs may play a partial or key role in the immune response to H. pylori, and this may provide potential targets for the future treatment of H. pylori-related diseases. © 2015, National Institute of Health. All rights reserved.


Yin M.,University of Chinese Academy of Sciences | Ren X.,University of Chinese Academy of Sciences | Zhang X.,Guangzhou Medical College | Luo Y.,Guangzhou RiboBio Co. | And 11 more authors.
Oncogene | Year: 2015

The tumor suppressor p53, nuclear factor-κB (NF-κB) and reactive oxygen species (ROS) have crucial roles in tumorigenesis, although the mechanisms of cross talk between these factors remain largely unknown. Here we report that miR-506 upregulation occurs in 83% of lung cancer patients (156 cases), and its expression highly correlates with ROS. Ectopic expression of miR-506 inhibits NF-κB p65 expression, induces ROS accumulation and then activates p53 to suppress lung cancer cell viability, but not in normal cells. Interestingly, p53 promotes miR-506 expression level, indicating that miR-506 mediates cross talk between p53, NF-κB p65 and ROS. Furthermore, we demonstrated that miR-506 mimics inhibited tumorigenesis in vivo, implicating that miR-506 might be a potential therapeutic molecule for selective killing of lung cancer cells.


Trademark
Guang Zhou Ribobio Co. | Date: 2012-10-16

Chemicals for use in agriculture, except fungicides, weedkillers, herbicides, insecticides and parasiticides; agricultural chemicals, except fungicides, weedkillers, herbicides, insecticides and parasiticides; chemical additives for insecticides; horticulture chemicals, except fungicides, herbicides, insecticides and parasiticides; substances for preserving seed; chemicals for preventing vine disease; chemical preparations for scientific purposes, other than for medical or veterinary use; chemical reagents, other than for medical or veterinary purpose; chemical substances, namely, reagents for analyses in laboratories, other than for medical or veterinary purposes; biological preparations for use in cell cultures, other than for medical or veterinary purposes.


Trademark
Guang Zhou Ribobio Co. | Date: 2012-10-16

Medicines for human purposes for the treatment of tumor, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, insomnia; pharmaceutical preparations for the treatment of tumor, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, insomnia; chemico-pharmaceutical preparations for the treatment of tumor, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, insomnia; drugs for medical purposes for the treatment of tumor, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, insomnia; veterinary preparations for the treatment of bird flu, Porcine Reproductive and Respiratory Syndrome, rabies, distemper, heartworm; medicines for veterinary purposes for the treatment of bird flu, porcine reproductive and respiratory syndrome, rabies, distemper, heartworm; biological preparations for veterinary purposes for the treatment of bird flu, porcine reproductive and respiratory syndrome, rabies, distemper, heartworm; chemical preparations for veterinary purposes for the treatment of bird flu, porcine reproductive and respiratory syndrome, rabies, distemper, heartworm; preparations for destroying noxious animals, namely, pesticides, insecticides; preparations for destroying noxious plants, namely, herbicides.

Loading Guangzhou RiboBio Co. collaborators
Loading Guangzhou RiboBio Co. collaborators